anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Embodiments of the instant disclosure relate to novel compositions and methods for treating a subject having genetic homocystinuria (HCU or other form of genetic homocystinuria). In some embodiments, compositions and methods disclosed herein concern improving efficacy of standard treatments (e.g. trimethylglycine) to reduce dietary compliance requirements and improve outcomes. In accordance with these embodiments, a subject having or suspected of developing classical cystathionine beta-synthase deficient homocystinuria (HCU) or other genetic form of homocystinuria can be treated with a polyamine or diamine or a precursor thereof or a combination thereof for example, in combination with trimethylglycine (e.g. betaine) or other genetic homocystinuria treatment. In other embodiments, a subject having or suspected of developing HCU or other genetic homocystinuria can also be treated with formate or formate derivative, or zinc and/or zinc-containing agent or other standard treatment in combination with a polyamine composition to treat HCU or RD or other form of genetic homocystinuria in the subject.
Participants in Cohort 6 (high, IM) will receive high doses of NDV-HXP-S at 1x109 EID50. Participants will ONLY enroll into Cohort 6 if Cohort 3 (low dose IM) did not have any SAEs that required additional participants. Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.
Venlafaxine will not be administered. They will be valuated both at T0 and after 4 weeks (T1).
<P>PROBLEM TO BE SOLVED: To provide a testosterone-5α-reductase inhibitor which has a testosterone-5α-reductase activity-inhibiting action, controls the production of a highly active dihydrotestosterone, has actions for inhibiting hypersteatosis, protein synthesis failure, the blood flow rate decrease of hair follicles, and the lowering of enzyme activity levels, little irritates the skins, has excellent safety for living bodies, and is useful as a raw material for cosmetics, to provide a skin cosmetic which contains a testosterone-5α-reductase inhibitor and improves sebaceous skins, and to provide a hair cosmetic which is effective for preventing alopecia and for growing the hair/restoring the hair.  <P>SOLUTION: This testosterone-5α-reductase inhibitor contains an extract of a Zosteraceae, Zostera sp. plant as an active ingredient. The skin or hair cosmetic contains a testosterone-5α-reductase inhibitor containing an extract of a Zosteraceae, Zostera sp. plant as an active ingredient.  <P>COPYRIGHT: (C)2007,JPO&INPIT
This study examines the safety and efficacy of using peak anti-Xa levels to achieve prophylactic enoxaparin (Lovenox, Sanofi-Aventis) levels in patients who underwent hepatic surgery. Prospectively enrolled patients undergoing major and minor hepatic procedures received postoperative enoxaparin dosing. The enoxaparin dose was adjusted to attain a peak anti-Xa level ≥ 0.20 U/ml. This group was compared to a historical cohort of patients who underwent similar procedures and received standard postoperative VTE chemoprophylaxis dosing. Inpatient postoperative VTE rates were higher in the control group when compared to the experimental group (0 patients [0.00%] vs 4 patients [8.16%]; P = .035). There was no statistically significant difference in number of postoperative blood transfusions, discharge hemoglobin, or in-hospital bleeding events. Adjusting enoxaparin dosing to achieve prophylactic peak anti-Xa levels of ≥0.20 IU/ml was associated with a reduced incidence of symptomatic inpatient postoperative VTE in patients who underwent hepatic surgery without increasing postoperative bleeding events.
Fexofenadine hydrochloride, the active ingredient of fexofenadine hydrochloride tablets, is a histamine H1-receptor antagonist with the chemical name (±)-4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-α, α-dimethyl benzeneacetic acid hydrochloride. It has the following chemical structure:

C32H39NO4•HCl M.W. 538.13

Fexofenadine hydrochloride is a white to off-white crystalline powder. It is freely soluble in methanol and ethanol, slightly soluble in chloroform and water, and insoluble in hexane. Fexofenadine hydrochloride is a racemate and exists as a zwitterion in aqueous media at physiological pH.

Fexofenadine hydrochloride is formulated as a tablet for oral administration. Each tablet contains 30, 60, or 180 mg fexofenadine hydrochloride (depending on the dosage strength) and the following excipients: colloidal silicon dioxide, croscarmellose sodium, hypromellose, iron oxide black, iron oxide red, iron oxide yellow, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, and titanium dioxide.

Fexofenadine hydrochloride tablets meet USP Dissolution Test 3.
The present invention relates to health care food used for regulating blood sugar and blood face for preventing and treating diabetes. The main components contain propolis, royal jelly, mulberry leaf and kudzuvine root. The effect of sugar reduction of propolis, meanwhile, the immunological regulation capability of human bodies is improved. The dosage forms comprise capsules, tablets, granules and oral liquid, and the dosage form of soft capsules is preferred. The present invention has the characteristics of rapid disintegration in bodies and easy absorption and utilization for human bodies. Natural Chinese herbal medicine kudzuvine root and mulberry leaf are extracted and concentrated on the technology. The total flavonoid content of kudzuvine root extract is larger than or equal to 40%, and the mulberry leaf polysaccharide content in mulberry leaf extract is larger than or equal to 20%. A great amount of active components of natural active components for reducing blood sugar and blood fat are concentrated in final products. Thereby, the effect of blood sugar reduction of the health-preserving health-care product of the present invention is improved greatly.
LOKELMA is a powder for oral suspension. The active ingredient in LOKELMA is sodium zirconium cyclosilicate, a potassium binder. Sodium zirconium cyclosilicate is a non-absorbed zirconium silicate that preferentially exchanges potassium for hydrogen and sodium. LOKELMA is an odorless, insoluble white to grey powder for oral suspension. It has a mean particle size of 20 µm and includes no more than 3% of particles with a diameter below 3 µm. Each 5 g of sodium zirconium cyclosilicate contains 400 mg of sodium.

The chemical formula of sodium zirconium cyclosilicate is Na~1.5H~0.5ZrSi3O9•2–3H2O.

Figure 1: Crystal Structure of Sodium Zirconium Cyclosilicate
BACKGROUND: The incidence of obesity is on the rise around the globe. Outside of the massive weight loss (MWL) patient population, knowledge of risk factors associated with abdominal body contouring (BC) is limited. This systematic review and meta-analysis assesses the impact of obesity has on cosmetic abdominal BC outcomes.
METHODS: A systematic review conducted in accordance with PRISMA 2020 was done. PubMed, Embase, Scopus, and COCHRANE databases were reviewed under search syntax "obesity," "abdominoplasty," "panniculectomy," and "body contouring" for articles. Cosmetic was defined as abdominoplasty or panniculectomy outside the context of MWL. Obesity was defined as BMI ≥ 30 kg/m2. Studies reporting postoperative outcomes with less than 50% of their population involving MWL patients were included. Postoperative outcomes were assessed by pooled analysis and meta-analysis.
RESULTS: Of 3088 initial studies, 16 met inclusion criteria, and nine were used for pooled and meta-analysis. Meta-analysis demonstrated that obesity was associated with more seromas (OR 1.45, 1.06-1.98, p = 0.02), hematomas (OR 2.21, 1.07-4.57, p = 0.03), and total surgical site occurrences (OR 1.99, 1.30-3.04, p = 0.0016). There was no significant difference in odds of any other complications. Analysis by obesity class showed no significant increase in odds in seromas or wound dehiscence.
CONCLUSIONS: This review demonstrates obesity increased odds of postoperative complications following cosmetic abdominal BC. However, risk of complications does not continue to increase with higher obesity class. A BMI ≥ 30 kg/m2 should not be a strict contraindication to cosmetic abdominal BC. Instead, plastic surgeons should evaluate patients on a case-by-case basis.
LEVEL OF EVIDENCE III: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Resistance training (RT) intensity will be estimated using the percentage of one-maximal repetition (1-RM) defined as the maximal weight liftable for ten maximal repetitions with proper form. The program will include five exercises (leg press, lat machine, leg extension, leg curl, bench press) and will start at high-volume low-intensity. RT will follow a periodization to reach high-intensity low-volume at the end of the intervention (week 12). The training sessions will start with five-minute of warm-up performed on a recumbent stepper and will end with five-minute of stretching (cool-down). RT's sessions will approximately last 45 minutes and will be interspersed with at least 48 hours of recovery.
OBJECTIVE: Percutaneous tracheostomy is routinely performed in adult patients but is seldomly used in the pediatric population due to concerns regarding safety and limited available evidence. This study aims to consolidate the current literature on percutaneous tracheostomy in the pediatric population.
METHODS: A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines was conducted. MEDLINE, EMBASE, CINAHL, and Web of Science were searched for studies on pediatric percutaneous tracheostomy (age ≤18). The Joanna Briggs Institute and ROBINS-I tools were used for quality appraisal.
RESULTS: Twenty-one articles were included resulting in 143 patients. Patient age ranged from 2 days to 17 years, with the largest subpopulation of patients (n = 57, 40 %) being adolescents (age between 12 and 17 years old). Main indications for percutaneous tracheostomy included prolonged ventilation (n = 6), respiratory insufficiency (n = 5), and upper airway obstruction (n = 5). One-third (n = 47) of percutaneous tracheostomies were completed at the bedside in an intensive care unit. Select studies reported on surgical time and time from intubation to tracheostomy with a mean of 13.8 (SD = 7.8) minutes (n = 27) and 8.9 (SD = 2.8) days (n = 35), respectively. Major postoperative complications included tracheoesophageal fistula (n = 4, 2.8 %) and pneumothorax (n = 3, 2.1 %). There were four conversions to open tracheostomy.
CONCLUSION: Percutaneous tracheostomy had a similar risk of complications to open surgical tracheostomy in children and adolescents and can be performed at the bedside in a select group of patients if necessary. However, we feel that consideration must be given to the varying anatomical considerations in children and adolescents compared with adults, and therefore suggest that this procedure be reserved for adolescent patients with a thin body habitus and clearly demarcated and palpable anatomical landmarks who require a tracheostomy. When performed, we strongly support using endoscopic guidance and a surgeon who has the ability to convert to an open tracheostomy if required.
Aging is an irreversible and continuous biological process involving intricate and interconnected mechanisms. The present work is focused on unravelling the anti-aging mechanisms of mealworm protein and protein-enriched fruit bar and vegetable soup in D-galactose-induced aged mice. Mealworm protein and enriched products significantly enhanced body weight, organ indices, and gut health. Behavioral assessments reflected enhanced neuroprotective effects. Mealworm protein and its enriched products demonstrated protective effects through anti-inflammatory activity with the highest reduction of TNFα (17.1 %), IL-6 (55.5 %), and IL-1β (75.1 %) levels and upregulated the anti-inflammatory marker (IL-4). Gene expression studies confirmed the induction of anti-aging effects by promoting metabolism, reducing cellular senescence, and enhancing anti-oxidant enzyme activity. The treatments extended telomere lengths by 3-4 times, further affirming the potential anti-aging efficacy of mealworm protein and its enriched products. Mealworm protein demonstrated positive effects on weight gain, anti-inflammatory responses, and telomere length; while fruit and vegetable products enhanced antioxidant activity, and positively influenced gut health. Further, a synergistic effect was observed by combining them, which resulted in improved overall anti-aging effect. The present work provides valuable insights into the multifaceted anti-aging mechanisms associated with mealworm protein and enriched products, highlighting their potential as functional foods with significant health-promoting effects.
The analysis of ancient DNA (aDNA) from human skeletal remains can provide useful insights when investigating archaeological finds. One popular application of aDNA is to examine genealogical relationships between individuals recovered at the same archaeological site. For the reconstruction of genealogical relationships, several genetic markers are commonly used: autosomal STRs, mitochondrial lineages (based on SNP-analysis) and Y-chromosomal haplotypes (based on Y-STR-analysis). In this paper, we present the additional opportunities that X-STRs provide in aDNA kinship reconstruction, especially in deficiency cases and for the examination of father-daughter relationships. Possible applications are demonstrated on a range of different kinship reconstructions: confirmation of half-siblingship in the Lichtenstein cave (Germany), exclusion of two potential father-daughter relationships in Goslar (Germany), investigation of three siblingships in Boilstädt (Germany) as well as the confirmation of a father-daughter relationship in Stolpe (Germany). This study shows that the analysis of X-STRs can contribute to the investigation of relationship constellations otherwise difficult to approach (e.g. father-daughter relationships) and that X-STRs are useful to support and complement autosomal STRs, mtDNA and Y-STR data.
Participants will first undergo a baseline PET/MR scan with \[18F\]-JNJ-64413739 on Day 1. Participants will receive oral dose of JNJ-55308942 (maximum dose 120 mg) on Day 2, followed by two post-treatment scans, one obtained at Tmax (4 hours postdose) and one at 24 hours postdose. Doses will be selected based on the principal investigator's discretion.
The present invention relates to a method for preparing kernel and shell type nanometer compound particles of hydroxyapatite and liposome, which belongs to the field of biomedical engineering. The method takes a water phase in liposome as a microreactor and takes inorganic compounds as raw materials to synthesize kernel and shell type nanometer compound particles of hydroxyapatite and liposome with a kernel and shell type microstructure characteristic in a bionic way, and drugs can be loaded in the compound particles. The surfaces of the compound particles are connected with compounds with specific biological functions for carrying out surface modification to the compound particles. The method has substantive characteristics and obvious progresses. The liposome is a drug carrier with very good application prospect, and can change the body distribution characteristics of drugs. A liposome film has good biocompatibility, and can generate specificity effects in a body through a plurality of reaction mechanisms. The hydroxyapatite embedded in the liposome and provided by the method can be more effectively applied to the fields of cancer treatment, drug transmission and bone defect repair.
The present invention relates to a brain tonic food and the manufacturing method. The brain tonic food contains the following components based on weight percent: linseed oil 93-97 percent, zinc citrate 1-2 percent and retinol 0.01-0.05 percent. The manufacturing method of the brain tonic food has the following steps. Firstly, retinol, vitamin E and linseed oil are mixed together and agitated evenly. Secondly, zinc citrate and selenocysteine are added. Lastly, folic acid is added and mixed evenly, and oil colloidal substances can be formed. The components and the contents in the present invention are optimally selected, and the produced brain tonic food has obvious effects of stimulating the brain development of embryos and infants.
Social isolation has been linked to a range of psychiatric issues, but the behavioral component that drives it is not well understood. Here, a genome-wide associations study (GWAS) was carried out to identify genetic variants that contribute specifically to social isolation behavior (SIB) in up to 449,609 participants from the UK Biobank. 17 loci were identified at genome-wide significance, contributing to a 4% SNP-based heritability estimate. Using the SIB GWAS, polygenic risk scores (PRS) were derived in ALSPAC, an independent, developmental cohort, and used to test for association with self-reported friendship scores, comprising items related to friendship quality and quantity, at age 12 and 18 to determine whether genetic predisposition manifests during childhood development. At age 18, friendship scores were associated with the SIB PRS, demonstrating that the genetic factors can predict related social traits in late adolescence. Linkage disequilibrium (LD) score correlation using the SIB GWAS demonstrated genetic correlations with autism spectrum disorder (ASD), schizophrenia, major depressive disorder (MDD), educational attainment, extraversion, and loneliness. However, no evidence of causality was found using a conservative Mendelian randomization approach between SIB and any of the traits in either direction. Genomic Structural Equation Modeling (SEM) revealed a common factor contributing to SIB, neuroticism, loneliness, MDD, and ASD, weakly correlated with a second common factor that contributes to psychiatric and psychotic traits. Our results show that SIB contributes a small heritable component, which is associated genetically with other social traits such as friendship as well as psychiatric disorders.
BACKGROUND: Chronic lung allograft dysfunction (CLAD) is the leading long-term cause of poor outcomes after transplant and manifests by fibrotic remodeling of small airways and/or pleuroparenchymal fibroelastosis. This study evaluated the effect of pirfenidone on quantitative radiographic and pulmonary function assessment in patients with CLAD.
METHODS: We performed a single-center, 6-month, randomized, placebo-controlled trial of pirfenidone in patients with CLAD. Randomization was stratified by CLAD phenotype. The primary outcome for this study was change in radiographic assessment of small airways disease, quantified as percentage of lung volume using parametric response mapping analysis of computed tomography scans (PRMfSAD); secondary outcomes included change in forced expiratory volume in 1 second (FEV1), change in forced vital capacity (FVC), and change in radiographic quantification of parenchymal disease (PRMPD). Linear mixed models were used to evaluate the treatment effect on outcome measures.
RESULTS: The goal enrollment of 60 patients was not met due to the coronavirus disease of 2019 pandemic, with 23 patients included in the analysis. There was no significant difference over the study period between the pirfenidone vs placebo groups with regards to the observed change in PRMfSAD (+4.2% vs -0.4%; p = 0.22), FEV1 (-3.5% vs -3.6%; p = 0.97), FVC (-1.9% vs -4.6%; p = 0.41), or PRMPD (-0.6% vs -2.5%; p = 0.30). The study treatment tolerance and adverse events were generally similar between the pirfenidone and placebo groups.
CONCLUSIONS: Pirfenidone had no apparent impact on radiographic evidence of allograft dysfunction or pulmonary function decline in a single-center randomized trial of CLAD patients that did not meet enrollment goals but had an acceptable tolerance and side-effect profile.
The invention relates to an implant with a coating (23) which releases silver ions in the human body and as a result has antimicrobial action. According to the invention, a first surface component of the coaling (23) is formed by an anode material (25). A second surface component of the coating (23) is formed by a cathode material (26). The cathode material is higher in the electrochemical voltage series than the anode material (25). The cathode material (26) and the anode material (25) are connected to one another in an electrically conductive manner. Together with the body electrolyte in the environment of the implant, the anode material (25) and the cathode material (26) form a multitude of local galvanic elements. The antimicrobial action of the coating (23) is improved as a result.
Common techniques introduced for horizontal ridge augmentation are Guided Bone Regeneration (GBR), there are many techniques for ridge augmentation involves the use of bone grafting materials, barrier membranes, possibly some tenting/fixation screws. For successful GBR, stability of bone graft, space maintenance, angiogenesis, and tension free primary suture are essential. Space maintenance with particulate bone graft should be provided during healing period. However particulate bone graft is easily migrated when grafted on the large horizontal bone defect. To reconstruct large bony defect or for the 3-dimensional ridge augmentation, bone tack on the collagen membrane or titanium mesh is required to contain particulate bone graft during healing but these procedures are surgically time consuming and technique sensitive.

Sticky bone is biologically solidified bone graft which is entrapped in fibrin network. Sticky bone graft doesn't scatter because particulate bone powders are strongly interconnected each other by fibrin network.
The invention discloses an application of puerarin in regulating and controlling myocardial cell Caveolin-3 (CAV 3) protein and treating diabetic cardiomyopathy (diabetic cardiomyopathy, DCM). The related efficacy of puerarin is researched at the cellular and molecular level, and the result shows that the high-sugar high-fat (HGHL) treatment inhibits the activity of myocardial cells and promotes apoptosis. Puerarin reduces myocardial cell injury caused by HGHL, and inhibits NF- κB and p38MAPK pathways. In addition, puerarin positively regulates the expression of CAV3 protein, while silencing the expression of CAV3 protein can prevent the influence of puerarin on the expression of cell inflammatory factor IL-6. Finally, CAV3 regulates the expression of inflammatory factor IL-6 via NF-. Kappa.B and p38MAPK pathways. Therefore, puerarin can inhibit NF- κB and p38MAPK pathways by up-regulating expression of CAV3 protein in H9c2 myocardial cells, thereby reducing HGHF-induced cell damage, providing a new thought for DCM treatment, and providing scientific basis for widening medical application of puerarin.